Myocardial Infarction Pathophysiology

The recognition that chest pain could arise from a discrete vascular event within the heart—rather than a generalized imbalance of humors—required centuries of anatomical and clinical observation. Early physicians noted the association between anginal symptoms and post-mortem coronary artery disease, yet the precise mechanism linking arterial obstruction to myocardial tissue death remained elusive until the twentieth century. The evolution from descriptive autopsy findings to the modern understanding of myocardial infarction (MI) as an acute thrombotic event superimposed on atherosclerotic plaque represents one of the most consequential advances in cardiovascular medicine, fundamentally reshaping both diagnosis and therapy.

These milestones collectively framed the central question that defines MI pathophysiology: how does disruption of coronary blood flow translate into irreversible cardiomyocyte death, and what determines the extent and clinical severity of the resulting necrosis? Answering this question requires integrating concepts from vascular biology, cellular metabolism, inflammatory signaling, and tissue remodeling—topics that form the foundation of the sections that follow.

Myocardial infarction is fundamentally defined as myocardial cell death due to prolonged ischemia—a sustained imbalance between oxygen supply and myocardial oxygen demand. Understanding MI pathophysiology requires mastery of several interconnected concepts that govern how the heart responds to ischemic insult, from the initial vascular event through cellular injury to the final tissue outcome.

The concept of the wavefront phenomenon, first described by Reimer and Jennings in the 1970s, is central to understanding infarct pathophysiology. Necrosis does not occur uniformly across the full thickness of the ventricular wall at the moment of coronary occlusion. Instead, cell death begins in the subendocardial zone—the innermost layer of the myocardium—where wall stress is greatest, oxygen extraction is highest, and collateral flow is most tenuous. Over the ensuing hours, the necrotic front advances transmurally toward the epicardium. This time-dependent progression is the biological basis for the clinical axiom that "time is muscle."

Several factors modulate the rate of wavefront progression. The presence of collateral circulation can slow the necrotic front by providing residual perfusion through alternative arterial pathways, effectively extending the window for salvage. Conversely, elevated myocardial oxygen demand—driven by tachycardia, increased afterload, or sympathetic activation—accelerates the transition from ischemia to infarction. The metabolic state of the myocardium also matters: preconditioning by brief ischemic episodes can activate endogenous cardioprotective pathways that delay cell death, a phenomenon known as ischemic preconditioning.

The transition from reversible ischemia to irreversible necrosis involves a cascade of interconnected biochemical derangements at the cellular level. Under normal conditions, the myocardium derives more than 90% of its ATP through oxidative phosphorylation in mitochondria, primarily oxidizing fatty acids with a smaller contribution from glucose and lactate. When coronary flow ceases, oxygen delivery falls below the critical threshold needed to sustain aerobic metabolism, triggering a sequence of metabolic, ionic, and structural changes.

Phase 1: Metabolic Shift (0–10 minutes)

Within seconds of coronary occlusion, the oxygen tension in the affected myocardium drops precipitously, halting the electron transport chain. The cell shifts to anaerobic glycolysis as its primary ATP source, generating only 2 molecules of ATP per glucose compared to approximately 36 under aerobic conditions. This dramatic reduction in ATP yield—a roughly 18-fold decrease—means that cellular energy stores become depleted within minutes. Simultaneously, anaerobic glycolysis produces lactate and hydrogen ions, leading to intracellular acidosis. The falling pH inhibits glycolytic enzymes, creating a negative feedback loop that further impairs even this limited ATP production.

Phase 2: Ionic Derangement (10–30 minutes)

ATP depletion has profound consequences for ion homeostasis. The Na⁺/K⁺-ATPase, which normally maintains the resting membrane potential by extruding sodium and importing potassium, fails as ATP levels drop. Intracellular sodium rises, drawing water osmotically into the cell and causing cellular swelling (hydropic change). Simultaneously, the intracellular acidosis activates the Na⁺/H⁺ exchanger to extrude excess H⁺, further increasing intracellular Na⁺. The rising Na⁺ concentration then reverses the Na⁺/Ca²⁺ exchanger, flooding the cytoplasm with calcium. Elevated cytoplasmic Ca²⁺ activates destructive enzymes—phospholipases, proteases, and endonucleases—that begin degrading cell membranes, structural proteins, and chromatin.

Phase 3: Irreversible Injury (>20–40 minutes)

The point of no return is marked by two critical ultrastructural events: the development of mitochondrial permeability transition pore (mPTP) opening and irreparable damage to the sarcolemmal membrane. The mPTP, a non-selective channel in the inner mitochondrial membrane, opens in response to calcium overload and oxidative stress, collapsing the mitochondrial membrane potential and abolishing any residual capacity for oxidative phosphorylation. Sarcolemmal disruption allows intracellular contents—including troponins, creatine kinase-MB, and myoglobin—to leak into the interstitium and ultimately the bloodstream, forming the biochemical basis for cardiac biomarker detection. At this point, even restoration of blood flow cannot rescue the affected cardiomyocytes.

The Fourth Universal Definition of Myocardial Infarction (2018) classifies MI into five types based on the underlying pathophysiological mechanism. This classification is clinically essential because it determines treatment strategy: a Type 1 MI caused by plaque rupture requires antiplatelet therapy and percutaneous coronary intervention, whereas a Type 2 MI caused by supply-demand mismatch requires correction of the precipitating condition. Understanding these distinctions reflects the principle that "myocardial infarction" is not a single disease but a final common pathway that can be reached through multiple etiological routes.

STEMI vs. NSTEMI: Pathophysiological Distinction

The electrocardiographic distinction between ST-elevation MI (STEMI) and non-ST-elevation MI (NSTEMI) reflects a fundamental difference in coronary pathology. In STEMI, the culprit artery is completely occluded by thrombus, producing transmural ischemia manifesting as ST-segment elevation on the ECG. The injury current flows from the fully ischemic transmural zone toward the uninjured myocardium, creating the characteristic ST elevation in leads facing the infarcted territory. In NSTEMI, the thrombus is sub-occlusive or associated with distal microembolization, producing subendocardial (non-transmural) ischemia that appears as ST depression or T-wave inversion. This pathophysiological distinction drives the urgency of intervention: STEMI mandates emergent reperfusion within 90 minutes (door-to-balloon time), whereas NSTEMI is managed with an early invasive strategy guided by risk stratification.

The following scenario integrates the pathophysiological principles discussed above into a clinical context. Work through each step to connect the underlying mechanisms with clinical findings.

The complications of myocardial infarction follow a predictable temporal pattern that reflects the underlying phases of tissue injury, inflammation, and repair. Understanding this timeline is essential for anticipating, recognizing, and managing post-MI morbidity and mortality. The following table organizes the major complications according to their typical time of onset relative to the initial infarction.

The pathophysiology of myocardial infarction intersects with several advanced concepts in cardiovascular medicine and molecular biology. As healthcare students progress into clinical practice and research, the foundational mechanisms described in this lesson extend into areas of active investigation, from biomarker refinement to regenerative medicine.

One of the most active areas of translational research involves reperfusion injury mitigation. While timely reperfusion remains the cornerstone of STEMI treatment, the recognition that reperfusion itself contributes to final infarct size has motivated trials of pharmacological and mechanical adjuncts aimed at attenuating the oxidative and inflammatory burst that accompanies flow restoration. Remote ischemic conditioning—brief cycles of ischemia and reperfusion applied to a limb during primary PCI—has shown promise in reducing infarct size in some trials by activating endogenous cardioprotective signaling pathways, including the RISK (Reperfusion Injury Salvage Kinase) and SAFE (Survivor Activating Factor Enhancement) cascades. These advances underscore how mechanistic understanding of MI pathophysiology continues to drive therapeutic innovation.